Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Urinary analgesics

This article was originally published in The Tan Sheet

Executive Summary

The availability of OTC urinary tract infection diagnostic kits in conjunction with the condition's "readily recognizable symptoms" combines to create a safe atmosphere for self-medication using phenazopyridine hydrochloride, Polymedica Pharmaceuticals maintains in recent comments filed with FDA. Current labeling requirements "are sufficient to ensure safe and effective" OTC consumer use of the ingredient, the Azo Standard marketer says. OTC urinary analgesic products "clearly instruct the consumer to seek appropriate medical attention if symptoms persist beyond a specific time," the firm adds, echoing separate comments filed by CHPA (1"The Tan Sheet" July 12, 2004, p. 6)...
Advertisement

Related Content

Urinary Analgesics’ Safe History Justifies Monograph Inclusion – CHPA
Urinary Analgesics’ Safe History Justifies Monograph Inclusion – CHPA

Topics

Advertisement
UsernamePublicRestriction

Register

PS097101

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel